Raghav Sundar

It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert @oncodaily nejm.org/doi/full/10.10…

Grateful for this award from MASCC. We have been working closely with @RichPaxman to build a device to reduce chemotherapy induced peripheral neuropathy. Awaiting results from the ICE COMPRESS trial. This has been a massive team effort! swog.org/clinical-trial…

Gastric cancer @TheLancet doi.org/10.1016/S0140-… 👏Excellent and comprehensive summary from screening to targeted therapies by @sundar__raghav @LizzySmyth1 @YJanjigianMD @KoheiShitara @HannekevanLaar1 @myESMO

A tribute to Dr. Agatsuma was a meaningful moment during my DESTINY-Gastric04 presentation at #ASCO25 with @NEJM publication. I deeply respect him and the entire team behind the development of T-DXd. @ASCO @OncoAlert @DaiichiSankyo @DaiichiSankyoUS @AstraZeneca @Oncology_at_AZ

📢It's #ESMO election time! I am delighted to be nominated for ESMO Director of Education 😊 ALL the nominees are fantastic representing the global @myESMO community 🌍 🙏for all the good wishes Rules this year for social media so that's it from me! Now please vote 🗳️

Cancer patients with B cell malignancies and differential expression of CD24, CDK14 and PLEKHG1 have highest risk of breakthrough infections after SARS-CoV2 vaccination nature.com/articles/s4154… Thank you @kuanrongchan @sundar__raghav for the collaboration! 😎

Thrilled to share our latest Review on Gastric Cancer in the @TheLancet covering the latest in the treatment and management of this illness @LizzySmyth1 @KoheiShitara @HannekevanLaar1 @MarkarSheraz @YJanjigianMD & Izuma Nakayama. thelancet.com/journals/lance…

String of #AACR25 posts coming up! Proud of the work by @josephjzhao unraveling epigenetic mechanisms of peritoneal metastases in gastroesophageal cancers. @KlempnerSam @JohnnyOngCA

Published today simultaneously with #AACR25 our work on colorectal cancer peritoneal metastases in Clinical Cancer Research. aacrjournals.org/clincancerres/… slowly heading toward the goal of treating this difficult disease with novel therapeutics

Grateful to be given the opportunity to share our work on tumor evolution in gastric cancer and peritoneal metastases at #AACR25 with Dr Sun Young Rha @KlempnerSam @josephjzhao @choong_kun

.@sundar__raghav shares how spatial heterogeneity is driven to an evolution over space and time in #gastriccancer. As the tumor morphs, so does the TME, warranting different considerations in treatment based on heterogeneity differences. #AACR25 @YaleGICancers @SmilowCancer

Read more about #AACR25 speaker @sundar__raghav's efforts to chart gastric cancer evolution through tumor ecosystems and metastatic pathways in this @CD_AACR paper from this month's issue doi.org/10.1158/2159-8…

Excited to be in Chicago for #AACR25! Feels a little surreal to be at McCormick but not for ASCO! Looking forward to listening to some amazing science and breakthroughs in cancer biology and therapeutics. @KlempnerSam @josephjzhao

This afternoon starting at 2pm CDT, Drs. Barbara Burtness, @moeinrajaei, @JeffTownsend, Longgang Zhao, and @sundar__raghav present research during the first poster session of #AACR25. @SmilowCancer @YaleMed @YNHH @YaleNursing

Thursday, April 24 at 6pm, @sundar__raghav will moderate the next @YaleGICancers CME Webinar spotlighting #GastroesophagealCancers. Join for presentations + discussion from Drs. Daniel Boffa, @yalesurgery, @kevin_du, and @DrJoannaGibson. ➡️Register: bit.ly/4jRXby5…

Honored to give the Keynote lecture at the Sixth Annual Paul R. O’Hara Esophagogastric Symposium in the University of Colorado Cancer Center. Sharing our work in gastroesophageal cancer and peritoneal metastases. Many thanks to @SunnieSKim for inviting me to speak!

From the April issue:Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution brnw.ch/21wRND9 By Haoran Ma, Supriya Srivastava, @sundar__raghav, Patrick Tan, and colleagues @dukenus @NUSingapore @astar_gis

Excited to share biomarker analysis of CM649 @NatureMedicine @YJanjigianMD Nivo benefit was enriched in TMB-H> EBV and GS > CIN. Targeted tx is needed for CIN. Nivo+Ipi benefit was seen in Treg↑ (FOXP3+CCR8), supporting Treg or CCR8 targeting tx in GC. nature.com/articles/s4159…

Mattehorn study showed EFS improvement and strong OS trend with FLOT+duravalumab. Great news to establish the global standard for fit patients with locally advanced gastric/GEJ cancer. Looking forward to the detail.@OncoAlert @oncodaily astrazeneca.com/media-centre/p…

Just published @JAMAJournal with @KlempnerSam and @JeeyunM jamanetwork.com/journals/jama/… Our Editorial on GEMSTONE-303 with sugemalimab and chemo. Key takeaway: PD-L1 inhibition shows similar efficacy to PD-1. More options for patients, but no clear advantage over existing treatments.